Strategic Partnerships Vivacelle Bio is actively engaging with industry events and regional expansion, including BIO Partnering @ JPM Week 2025 and Sub-Saharan Africa market outreach, presenting a clear opportunity to partner with regional distributors, healthcare providers, and research networks to accelerate trials and adoption.

Clinical Pipeline The lead product VBI-1 targets hypovolemia with a potential safety and efficacy edge over current fluids, while VBI-S aims at septic shock. This creates cross-sell potential across trauma centers, emergency departments, ICU networks, and war/aid medicine programs seeking advanced resuscitation therapies.

Regulatory Readiness FDA green light for Phase IIa in hypovolemia indicates a regulatory pathway that can be leveraged in discussions with hospital systems and payer partners, enabling joint clinical and health economic studies to support adoption.

Market Access Global need for safer fluid resuscitation and nitric oxide-modulating therapy positions the company to pursue strategic collaborations with government health agencies, global health NGOs, and regional distributors in high-need markets such as Sub-Saharan Africa.

Commercial Signals Revenue trajectory indicates a small, specialized biotechnology company with potential for scaled partnerships; target mid-to-late stage collaborations and licensure deals to broaden reach while aligning with ongoing clinical milestones and funding rounds.